Global Home Global Home
UNITED STATES

 

A New Era in Anti-Infectives

 

Latest News
..........................................

May 23rd, 2013
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2013 Financial Results and Conference Call

May 1st, 2013
Oculus Innovative Sciences Announces New Regulatory Approvals for Microcyn(R)-Based Antiseptic Products in Panama and El Salvador

April 24th, 2013
Oculus Innovative Sciences Announces New Regulatory Approvals and Target Launch Dates for Three New Microcyn(R)-Based Products in Middle East Countries

April 10th, 2013
Oculus Innovative Sciences to Rollout Five New Microcyn(R) Technology-Based Products in Singapore and Malaysia

April 4th, 2013
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of Three New International Patents for Microcyn(R) Technology

March 28th, 2013
Oculus Innovative Sciences Announces Reverse Split of Common Stock

March 26th, 2013
Oculus Innovative Sciences Expands Regulatory Claims for Microcyn-Based Advanced Wound Management Products in Europe

March 20th, 2013
Oculus Innovative Sciences Appoints Jerry McLaughlin to Its Board of Directors

March 14th, 2013
Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar Management Study

March 12th, 2013
Oculus Innovative Sciences Announces Closing of Public Offering of 8,625,000 Shares of Common Stock

More »


About Oculus

Oculus Innovative Sciences is a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, surgical, wound care, animal healthcare and others, and has commercialized products in the United States, Europe, India, China and Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America.